Improving

Human Health

We invest in early-stage life-science companies with the potential to enhance human well-being and quality of life.

ABOUT US LET'S TALK

Continuing to

Grow & Invest

We are an evergreen fund that has a long-term investment perspective.

OUR APPROACH LET'S TALK

Focusing on the

Mid-Atlantic Region

We invest in life-science companies in the Mid-Atlantic region.

OUR CRITERIA LET'S TALK

Launching Successful

Companies

Our portfolio companies have attracted over $4.4 billion of external capital to support their growth.

OUR PORTFOLIO LET'S TALK

Latest News

All Accelerated Biosciences Acuity Pharmaceuticals Allevi Alteris Annovis Atalan Avid Radiopharmaceuticals Bainbridge Health BioAdvance News BobcatBio Ceptaris Cohero Health Concarlo Therapeutics CrossBridge Eliksa Therapeutics ENB Therapeutics General Halo Labs Hanimune Therapeutics HealthQx HueDx ImmunoGenesis Immunome InfraScan Innervace Intezyne iView Therapeutics KaloCyte Kayothera Keriton Ladder Bio Latus LumenVu Mebias Discovery Melior Discovery Midway Pharmaceuticals Novira Therapeutics NuPathe Oncora Medical Onspira Therapeutics Opsidio Ossianix Palvella Therapeutics Phrase Health Pillo Health Portfolio News Protez Pharmaceuticals PST Relmada Therapeutics Renovacor Ride Health Senzo Strados The One Health Company Tolerance Bio Treventis Corporation Venatorx Pharmaceuticals Vesteck Vittoria Biotherapeutics Wellsheet

Healthcare AI’s Next Competitive Moat Isn’t Technology. It’s Regulation

Tolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa from NeoImmuneTech to Advance Programs Targeting Thymic Function and Immune Resilience

BioAdvance Capital Advances Life Sciences Innovation with New Investments and Portfolio Momentum

Melior Discovery Selected as Preclinical CRO to Support Linnaeus Therapeutics· ARPA-H PROSPR Program

Who We Are

OUR COMPANY

Who We Support

OUR PORTFOLIO